ArticleFrontiers in medicine2025
Genetic mutations in lymphocytic variant of hypereosinophilic syndrome: study of five siblings.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: Lymphocytic variant hypereosinophilic syndrome (L-HES) is a rare subtype of hypereosinophilic syndrome driven by aberrant T-cell clones that promote eosinophilia through interleukin-5 (IL-5) overproduction. While clonal T-cell receptor (TCR) rearrangements are a hallmark, the underlying genetic landscape remains poorly defined. Methods: We report a familial case series involving five siblings, three symptomatic and two asymptomatic, with comprehensive clinical, immunophenotypic, and genomic evaluations. Whole-exome sequencing (WES) was performed to identify rare germline variants contributing to disease susceptibility. The index patient (EOS1) presented with clonal CD3 Results: EOS1 exhibited classic L-HES features and a positive TCR clonality test. Exome analysis revealed several nonsynonymous variants of uncertain significance in genes related to transcriptional regulation (ZNF257, MLLT1, BRD9), immune signaling (TESPA1, LRCH4, DHX58), and oncogenesis (CTAGE4, RGPD5). No STAT3 or recurrent mutations were identified. Several variants were shared among affected siblings but absent in unaffected controls, suggesting a possible hereditary predisposition. Discussion: This study highlights novel germline variants potentially associated with L-HES pathogenesis and expands the genomic spectrum beyond previously implicated somatic mutations. Our findings support the role of immune dysregulation and genetic predisposition in L-HES and underscore the importance of broader genomic profiling in familial cases. Functional validation and long-term monitoring are essential for risk stratification and early detection of malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.